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ABSTRACT 
 
On the basis of the recently recognized potential of bone marrow stem cells to give rise to 
hepatocytes, we here investigated the role of G-CSF priming PBMCs played in the liver of 
cirrhotic rats. The animal model of liver cirrhosis was induced by injecting CCl4 in SD rats, 
and G-CSF was administered in hematopoietic stem cell mobilization doses. After the liver 
cirrhosis model was established, the female cirrhotic rats were divided into two groups. Group 
I only received G-CSF mobilization, group II received G-CSF mobilized PBMCs transplanted 
from the male cirrhotic rats. PKH26 staining and sex-determining region for the 
Y-chromosome gene were used to trace the transplanted cells. Liver function related factors 
were assayed under the animal automatic biochemistry analyzer, and the liver pathological 
changes were evaluated by HE staining. The comparative liver functions of the two groups 
were investigated by analysis of two sample t-tests. A P value of <0.05 was considered as 
significant in all analyses. Our results showed that the transplanted PBMCs could locate in the 
livers of the female rats. In addition, compared with the group I, rats in group II displayed 
significant liver improvement in serum ALB, ALT, AST and TBIL (p<0.05). However, the 
semi-quantitative classification of the liver pathological changes in both groups did not indi-
cate a significant difference (p>0.05). The results indicated that mobilized PBMC transplant 
could contribute to liver function in cirrhotic livers, which might be an alternative therapy for 
liver cirrhosis. 
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INTRODUCTION 
 
Liver cirrhosis is one of the most com-
mon liver diseases in China (Liu and Fan, 
2007) . Currently, liver transplantation is the 
only effective therapy. However, its wide-
spread use is still limited by the following 
factors: lack of donor organs, risk of rejec-
tion, operative damage, and high costs. 
Therefore, it is very important to find an 
alternative therapy for liver cirrhosis.  
Recent evidence shows that bone mar-
row (BM) derived stem cells could be con-
verted into hepatocyte-like cells in vitro 
(Ruhnke et al., 2005; Yan et al., 2007; 
Khurana and Mukhopadhyay, 2008). In 
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vivo, several reports demonstrated that BM 
derived stem cells might accelerate the re-
covery and improvement of liver function 
in the animal model of liver injury (Lagasse 
et al., 2000; Körbling et al., 2002; Wang et 
al., 2003) . Moreover, several recent clinical 
trials showed G-CSF mobilization or 
G-CSF mobilized bone marrow-derived 
hematopoietic stem cells could contribute to 
liver function in cirrhotic livers (Terai et al., 
2006; Yannaki et al., 2006; am Esch et al., 
2005; Gordon et al., 2006; Gaia et al., 
2006). Taken together, these findings sug-
gest that G-CSF mobilization or G-CSF 
priming of peripheral blood monocytes 
transplantation could contribute to liver 
function in cirrhotic livers. 
In previous studies we have demon-
strated that PBMCs from patients with de-
compensated liver cirrhosis can differenti-
ate into functional hepatocytes both in vitro 
and in vivo (Yan et al., 2007, 2008). In ad-
dition, simple randomized clinical trials 
also demonstrated that autologous PBMC 
transplantation played one important role 
for decompensated liver cirrhosis (Han et 
al., 2008). Although the preliminary results 
seemed to be favorable, liver biopsy was 
not undertaken in these patients and its po-
tential mechanism was still unclear. 
In this study, we established an animal 
model of liver cirrhosis, and then trans-
planted the mobilized PBMCs into the cir-
rhotic rats to observe both the kinetics of 
liver function related factors and the 
changes in liver histopathology. Our results 
showed that GSF priming PBMCs could 
improve the liver function of the cirrhotic 
rats significantly, but similar changes in 
liver histopathology were observed between 
the G-CSF mobilization therapy and G-CSF 
mobilized PBMC transplantation therapy. 
This study indicated that mobilized PBMC 
transplantation might be an alternative 
therapy for liver cirrhosis. 
 
MATERIALS AND METHODS 
 
CCl4-induced liver cirrhosis model 
Female and male SD rats were 6 weeks 
old, weighing between 135 and 150 g. Rats 
were bred and maintained in an air-condi-
tioned facility with specific pathogen-free 
conditions, and were subjected to a 12:12-h 
day light/darkness and allowed unlimited 
access to food and water. Morphological 
and behavioral changes of the rats were 
monitored. The female or male liver cirrho-
sis model was induced by CCl4 injected 
intraperitoneally at a dose of 0.3 mL/100 g 
body weight of 60 mL/L CCl4 (Sigma, St. 
Louis, USA) dissolved in an equal volume 
of castor oil (Sigma, St. Louis, USA). The 
injection was given twice a week for 16 
weeks to establish liver fibrosis, and were 
subjected to the corresponding therapy only 
when animals displayed stable liver cirrho-
sis four weeks after the discontinuation of 
carbon tetrachloride (Nussler et al., 2006). 
The same volume of castor oil alone was 
used as a control. Liver cirrhosis was de-
termined by histopathological examination. 
 
G-CSF mobilization and PBMC admini-
stration 
After the decompensated liver cirrhosis 
model was established, the female cirrhotic 
rats were divided into two groups. Group I 
only received G-CSF mobilization, with 
recombinant human granulocyte colony 
stimulating factor  (rhG-CSF, Qi Lu Phar-
maceutical Co, Ltd., China) at 5 µg/kg/d 
administered subcutaneously daily for 4 
days as a control( Gaia et al., 2006); group 
II received sex-matched mobilized periph-
eral blood monocyte transplantation. 
PBMCs were injected intravenously into 
the rats’ tails after suspension in phosphate 
buffer saline. All animal experiments re-
ceived approval from the institutional ani-
mal care committee. 
 
Detection of PKH26 labeled PBMCs 
Liver tissue was analyzed two weeks 
after injection of PBMCs. Five-micrometer 
frozen sections were made and then the sec-
tions were placed directly under a fluores-
cence microscope. Green fluorescence was 
chosen to emit the section. 
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Primer in situ labeling for SRY gene 
Liver tissues of female rats were col-
lected for detecting the male sex-determin-
ing Region Y (SRY) gene at week two of 
the transplantation, and primed in situ la-
beling (PRINS) was performed according to 
the previous reports (Koch et al., 1989, 
1995), with Dig-11-dUTP used as the report 
molecules. Primers of SRY were designed 
according to nucleotide sequences of the 
human SRY. The oligonucleotide primers 
used were: 
Forward: 5’-AGGCGCAAGTTGGCTCAAC-3’ 
Reverse:  5’-GGCCTTTTTTCGGCTTCTG-3’ 
(101bp). 
 
Examination of the level of liver function 
related markers 
Venous blood of rats from different 
groups was collected from the retro-orbital 
vein at week twenty after CCL4-induction, 
also at week two, and two months after 
corresponding treatment. Liver function 
related factors including ALT, AST, TBIL, 
ALB, and CHO of the rats at different 
points were monitored by an animal auto-
matic biochemistry analyzer. 
 
Analysis of liver histopathology 
All the rats were terminated with CO2 
narcosis, and liver tissue was harvested for 
analysis. Liver samples were collected into 
PBS and fixed overnight in 40 g/L para-
formaldehyde in PBS at 4 °C. Serial 5-µm 
sections of the right lobes of the livers were 
stained with hematoxylin and eosin (HE) 
and were examined histopathologically. In 
accordance with the grading and staging 
criteria of chronic liver pathology (Jonker et 
al., 1990, 1992), we adopted the 
semi-quantitative method to evaluate the 
inflammatory, fatty degeneration, and ne-
crosis of the hepatocytes for rats of differ-
ent groups. Score criteria are the following: 
score 0 means no fatty degeneration, and 
necrosis, score 1 means mild fatty degen-
eration and necrosis, score 2 means moder-
ate fatty degeneration and necrosis, and 
score 3 means severe fatty degeneration and 
necrosis. The criteria of the liver fibrosis 
are the following: level 0 means normal 
liver tissue, level 1 means increased quan-
tity of collagen fibers but no compartment 
development, level 2 means no complete 
fiber compartment development, level 3 
means thinner of complete compartment 
development, and level 4 means thickening 
of complete compartment development. 
 
Statistical analysis 
Data are expressed as mean ± SD. The 
comparative liver functions of the two 
groups were investigated by analysis of two 
sample t-tests. A p value of <0.05 was con-
sidered as significant in all analysis. Statis-
tical analysis was done using the SPSS ver-
sion 13.0 software. 
 
RESULTS 
 
Characterization of cell origins 
The mobilized PBMCs from the cir-
rhotic rats were identified by markers spe-
cific for monocytes (CD14), HSCs (CD34, 
and CD133). The results showed that the 
percentage of CD34, CD133 expressed in 
the cells were about 20.1 %, 68.9 % respec-
tively, whereas the percentage of CD14 ex-
pressed in the PBMCs was about 89.4 %. 
Thus, we called the isolated cells in our ex-
periment PBMCs. 
 
The PBMCs staining 
With PKH26-GL, the isolated PBMCs 
from the male cirrhotic rats were labeled 
with 10 µM PKH26-GL. The percentage of 
labeled cells was more than 90 %, and the 
labeled PBMCs were shown as red under a 
fluorescence microscope (Figure 1A). After 
the labeled PBMCs were transplanted into 
the liver of female cirrhotic rats one month 
later, sporadic cells with red fluorescence 
among the hepatocytes were observed (Fig-
ure 1B), suggesting that PKH26-GL-labeled 
PBMCs migrated into the liver of female 
rats. 
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The result of PRINS on SRY gene 
The PRINS has been conducted suc-
cessfully to identify the rat SRY gene in the 
liver tissues of female cirrhotic rats. As is 
shown in Figure 2A, the rat SRY gene could 
be detected in the livers of the female rats 
that accepted the transplantation of PBMCs 
from the male, but could not be detected in 
the livers of the female rats that only ac-
cepted G-CSF mobilization (Figure 2B). 
This result indicated that the transplanted 
PBMCs could be located in the liver of the 
female cirrhotic rats. 
 
 
 
 
Figure 1A Figure 1B 
Figure 1: PKH26 stained PMBCs in vitro and in vivo (×100) 
A: PKH26 stained PMBCs in vitro; 
B: PKH26 stained PMBCs scattered in the cirrhotic liver of SD rats with red fluorescence 
 
Figure 2A Figure 2B 
Figure 2: sry gene was identified in the cirrhotic liver of the female rats (×100) 
A: sry gene was detected in the cirrhotic liver of the female rats that underwent the transplantation of 
PBMCs from the male cirrhosis; 
B: sry gene was not detected in the cirrhotic liver of the female rats that didn’t undergo the trans-
plantation of PBMCs from female rats. 
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Kinetics of the liver function in cirrhotic 
rats 
The liver functions of the rats treated 
with CCL4 showed significant damage on 
the 16th week. After the corresponding 
treatment, rats in both group I and group II 
displayed significant liver function im-
provement. Moreover, compared with those 
in group I, rats in group II displayed sig-
nificant liver improvement as shown in Ta-
ble 1. 
Liver histopathological changes of the 
cirrhotic rats 
After two months of PBMC transplanta-
tion, the rats were terminated and the 
pathological results indicated that the 
changes of fibrosis in rats from group I and 
group II were similar (Figures 3A, 3B), 
significantly improved over the untreated 
cirrhotic rats (Figure 3C). According to the 
grading and staging criteria of chronic liver 
pathology, we adopted the semi-quantitative 
method to evaluate the inflammatory, fatty 
degeneration, and necrosis of the hepato-
cytes. As is shown in Table 2, no significant 
difference was observed between the two 
groups (p>0.05). 
 
Table 1: Kinectics of liver function of the cirrhotic in different groups (n=6) 
ALT AST TBIL ALB CHO 
group 
U/L U/L µmol/L g/L µmol/L 
2w  I 284.88 ± 43.76 396.51 ± 41.80 11.50 ± 0.79 39.89 ± 3.09 1.25 ± 0.36 
    II 219.43 ± 58.64* 352.03 ± 34.68* 9.81 ± 1.00* 41.38 ± 5.02* 1.68 ± 0.32* 
2m  I 244.30 ± 30.53 248.12 ± 24.53 6.75 ± 0.63 40.68 ± 3.35 1.45 ± 0.39 
    II  119.18 ± 43.66* 167.83 ± 35.04* 4.98 ± 0.45* 40.36 ± 3.64 1.69 ± 0.31* 
2w  
Untreated group 
380.12 ± 20.04 411.6 ± 21.14 12.4 ± 0.61 23.98 ± 1.28 1.08 ± 0.21 
2m 
Untreated group 
348.23 ± 28.13 402 ± 38.20 11.69 ± 0.49 32.94 ± 2.03 1.19 ± 0.30 
*p＜0.05 was considered to have significant differences. 
2w: 2 week  2m: 2 month 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; ALB: albumin; 
CHO: cholesterol 
 
 
 Figure 3A Figure 3B Figure 3C 
Figure 3: Histopathological changes of the cirrhotic liver of the rats after different treatment (×200) 
A: Histopathological changes of liver of the cirrhotic rats that only accepted G-CSF mobilization ther-
apy 
B: Histopathological changes of liver of the cirrhotic rats that accepted G-CSF mobilization priming 
PBMCs transplant therapy 
C: Histopathological changes of liver of the cirrhotic rats that didn’t accept any therapy 
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Table 2: Pathological score of the cirrhotic rats in different groups after corresponding therapy 
(n=6, sx ± ) 
 
Group Fatty degeneration Necrosis Fibrosis 
Group I 2.32 ± 0.42 2.55 ± 0.71 1.48 ± 0.00 
Group II 2.36 ± 0.41 2.54 ± 0.51 1.47 ± 0.53 
Untreated 
group 2.67 ± 0.52 2.63 ± 0.64 3.86 ± 0.40 
 
 
DISCUSSION 
 
A variety of chronic injuries of the liver 
caused by viral hepatitis, alcohol abuse, 
drugs, autoimmune attack and metabolic 
diseases can lead to liver cirrhosis. In hu-
man and animal models bone mar-
row–derived hepatocytes have been identi-
fied in liver biopsies after sex-mismatched 
bone marrow transplantations (Theise et al., 
2000; Alison et al., 2000). Yet, our study 
showed the following: the cells infused into 
the cirrhotic rats were mobilized PBMCs, 
and the kinetics of liver functions of the 
cirrhotic rats were analyzed both in G-CSF 
mobilization group and G-CSF primed 
PBMC transplantation group. In addition, 
liver biopsy was made to compare the liver 
histopathological changes between the 
G-CSF mobilization and the G-CSF primed 
PBMC transplantation group.  
In recent years, clinical studies investi-
gating the efficacy of potential therapies of 
bone marrow-derived stem cells were initi-
ated, including cardiopathy (Schächinger et 
al., 2006), diabetic disease (Kawamura et 
al., 2006), system lupus erythema (Statkute 
et al., 2005), inflammatory bowel diseases 
(Ditschkowski et al., 2003), liver and pan-
creatic disease (Bengala et al., 2005). In our 
department, we have carried out PBMC 
transplantation to treat decompensated liver 
cirrhosis, and obtained favorable results 
(Yannaki et al., 2005) . To explain the last-
ing clinical amelioration of the cirrhosis, we 
established the animal model of liver cir-
rhosis, and then infused the mobilized 
PBMCs from the male cirrhotic rats into the 
female to observe the fate of the trans-
planted cells and their function. Results of 
cell tracing techniques including PKH26 
staining, and PRINS (primed in situ label-
ing analysis) of the rat Y chromosome 
showed that the transplanted PBMCs could 
migrate into the cirrhotic liver and then lo-
cate in the periportal vein through blood 
circulation. Moreover, this study showed 
the mobilized PBMC transplantation could 
improve liver function in cirrhotic rats sig-
nificantly more than those only receiving 
G-CSF mobilization therapy. However, 
similar histopathological changes were ob-
served in the two groups after the corre-
sponding treatment, which is consistent 
with the previous report. That the mobilized 
PBMCs could reverse liver cirrhosis to a 
certain extent might be explained by the 
following: G-CSF mobilized PBMCs se-
creted some chemokines, which might pro-
mote the transplanted PBMCs located in the 
injured liver; the mobilized PMBCs also 
secreted some cytokines, which promoted 
the proliferation of the transplanted cells or 
hepatic stem cells, and enhanced apoptosis 
of stellate cell of liver or the degeneration 
of the hepatic fibrous tissues.  
In conclusion, this study indicated that 
G-CSF mobilized PBMC transplantation 
could improve liver function in cirrhotic 
rats significantly. However, in reversing 
liver histopathology, the G-CSF mobiliza-
tion therapy showed a similar ability to re-
verse the liver histopathology with the 
G-CSF mobilized PBMC transplantation. 
This finding suggests that G-CSF mobilized 
PBMCs transplant might be considered as 
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another future protocol for liver cirrhosis 
treatment.  
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